Table 1.
Percentage of Eyes Losing >15 Letters from Baseline VA
| Study | >15 Letter Loss at End of Year 1 | >15 Letter Loss at End of Year 2 |
|---|---|---|
| Pushpoth et al 201244 | 9.5 | 14.6 |
| Ross et al 201345 | 9.9 | N/R |
| Muniraju et al 201332 | 9.8 | 14.4 |
| UK AMD EMR. 201446 | 10 | 18 |
| Basheer et al 201522 | 8.1 | 11.5 |
| Talks et al 201636 | 8 | N/A |
| Eleftheriadou et al 201826 | 6.8 | 9.2 |
| Chandra et al 202041 | 5.6 | 13.3 |
Notes: It should be noted that baseline characteristics will be different between real-world studies and compared with registration clinical trials. The percentage of eyes losing >15 letters at 2 years was approximately 9% in the MARINA registration trial for ranibizumab. In the integrated analysis of 2-year VIEW 1 and 2 data, 7.6% of eyes lost >15 letters from baseline.
Abbreviations: N/R, not reported; N/A, not applicable.